Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders virtually on June 17, 2026 at 8:00 a.m. PT. Stockholders of record as of April 23, 2026, when 87,346,132 common shares were outstanding, are eligible to vote.
Investors will vote on electing four Class III directors to serve until the 2029 annual meeting, approving on an advisory basis the compensation of named executive officers, and ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Olema Oncology has appointed Dr. Prakash Raman as a Class II director, effective April 28, 2026, with his term running until the company’s 2028 annual stockholders’ meeting. The board determined he is an independent director under Nasdaq rules and reported no related-party transactions.
Under Olema’s non-employee director compensation policy, Dr. Raman received a nonstatutory stock option to purchase 24,150 shares, vesting in 36 equal monthly installments, and a separate nonstatutory option for 2,911 shares that vests in full on June 11, 2026, in each case conditioned on continued service. Olema highlighted his extensive business development and leadership experience across multiple biopharmaceutical companies as it advances palazestrant in two Phase 3 trials and OP-3136 in a Phase 1 study.
Olema Pharmaceuticals reports beneficial ownership filings by Invus and related persons. As of March 16, 2026, Invus Public Equities directly held 3,898,500 shares and Avicenna Life Sci Master Fund directly held 563,449 shares. The filing states 87,156,961 Shares outstanding as of March 11, 2026. The cover pages show each reporting person’s sole voting and dispositive power counts and calculated ownership percentages (for example, 4.5% and 0.6% on cover pages). Signatories certify the holdings were not acquired to change control.
OLMA reported Rule 144 sale notices for Common Stock by Shane W. Kovacs. The filing lists multiple sales between 01/13/2026 and 03/11/2026, including a sale of 241,999 shares on 03/09/2026 for $3,254,934.55. The report provides per‑trade share counts and gross proceeds for each listed transaction.
OLMA reports an insider sale filing: Shane W. Kovacs intends to sell 100,000 shares of Common Stock pursuant to an option (Option Granted 02/01/2023), with the sale noted for 03/16/2026.
The filing also lists multiple recent dispositions by Kovacs during the past three months, including sales of 241,999 shares on 03/09/2026 and 100,000 shares on 01/15/2026, each with the cash amounts shown in the record.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on next-generation targeted therapies for ER-positive breast cancer. The company’s lead oral CERAN/SERD candidate, palazestrant (OP‑1250), is in a pivotal Phase 3 monotherapy trial (OPERA‑01) in second/third-line ER+/HER2‑ metastatic breast cancer, with top-line data expected in the fall of 2026 and an NDA planned for 2027.
A second pivotal Phase 3 trial, OPERA‑02, is testing palazestrant with Novartis’ CDK4/6 inhibitor ribociclib in first-line ER+/HER2‑ metastatic disease, targeting top-line data in 2028 and a potential U.S. launch in 2029. Earlier-phase data show encouraging progression-free survival and tolerability both as monotherapy and in combination with CDK4/6 inhibitors.
The company’s second clinical candidate, OP‑3136, a KAT6 inhibitor, entered Phase 1 after FDA IND clearance in 2024, with first clinical data expected in the second quarter of 2026. Olema relies on third parties for manufacturing, has no approved products or product revenue, and highlights substantial capital needs and ongoing net losses as key risks.
Olema Oncology reported fourth-quarter and full-year 2025 results, highlighting progress in its breast cancer pipeline and a stronger balance sheet. The company raised approximately $218.5 million in a follow-on offering and ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities.
Net loss widened to $46.1 million for the quarter and $162.5 million for the year, mainly from higher research and development and corporate spending as Phase 3 trials for palazestrant and a Phase 1 study for OP-3136 advanced. Non-GAAP R&D and G&A expenses also increased as Olema built late-stage and future commercial capabilities.
The company expects initial OP-3136 clinical data in Q2 2026 and top-line Phase 3 OPERA-01 results for palazestrant in the fall of 2026, while preparing for a potential first commercial launch in late 2027.
OLMA insider filed a Form 144 proposing the sale of 50,000 shares of Common Stock. The filing lists an option-originated sale of $50,000 shares scheduled 03/11/2026 and shows multiple reported dispositions by Shane W. Kovacs in the prior three months, including 241,999 shares sold on 03/09/2026 and other sales dated between 01/13/2026 and 03/10/2026.
The entries show per-transaction cash proceeds for each sale; the filing records the sales as cash transactions and identifies Fidelity Brokerage Services LLC as a broker for an earlier position. This Form 144 documents proposed and recent insider sales rather than a company capital-raising action.
Shane W. Kovacs reported sales of Common Stock as shown on a Form 144. The filing lists multiple dispositions, including 100,000 shares on 01/15/2026 and 241,999 shares on 03/09/2026. The table shows share counts and gross proceeds for each sale between 01/13/2026 and 03/09/2026.
OLMA filed a Form 144 reporting proposed and completed sales of common stock by an affiliate. The filing lists proposed option-related sales dated 03/09/2026 (noting line items of 162,000 and 79,999 shares) and shows Shane W. Kovacs reported sales totaling 190,343 shares across dates from 01/13/2026 to 03/04/2026.